…in patients with TED, without concomitant steroids (vs placebo at Week 24).2-4
Complete either the PDF or DocuSign® option of the Patient Enrollment Form to get your patient started on TEPEZZA.
Hi I’m Kimberly Cockerham and I’m a board certified ophthalmologist with sub-specialty training in orbit, plastics and neuroophthalmology.
Thyroid eye disease is a vision-threatening, chronic disorder. Patients usual present with bulging of their eyes, redness, swelling, and complete disfigurement. They don’t feel good about how they look, they’re in pain. They’re angry, and frustrated. When somebody comes in and they’re experiencing these symptoms, what are they really going through?
It is very likely that a patient has seen multiple other practitioners with no results. I’ve had numerous patients who are approaching a decade or more of failed therapeutics. Now things are different.
Prior to January of 2020 when TEPEZZA was FDA approved as the first targeted treatment for thyroid eye disease, there weren’t a lot of options. Now I have TEPEZZA. It acts pretty quickly, and TEPEZZA makes the muscles behind the eye smaller. The redness and swelling go away. So, it’s given me another tool in my tool chest.
Because of TEPEZZA, my conversations with my patients have changed for the better. I have a patient, and she gave me a picture of herself just before the thyroid eye disease started. And then she showed me a picture of her in the midst of the disease, all alone, sad, frustrated. And then she sent me a picture just a couple of weeks after her last infusion, and her proptosis had improved, her eyes weren’t bulging, she was really looking much more like herself again, and there she was, with her son, her grandchild and just beaming.
Each patient’s thyroid eye disease journey is different, but it’s really rewarding to be part of these patients’ lives. Now, with TEPEZZA, I can help impact that journey.
Thyroid Eye Disease (TED) is a serious, chronic, progressive, and potentially vision-threatening autoimmune disease with variability in symptom presentation2,5
TEPEZZA has a novel, breakthrough mechanism in Thyroid Eye Disease (TED) designed to block IGF-1R, a key mediator1,2,6-8
Baseline
Post-Treatment (Week 24)
TEPEZZA is indicated for the treatment of Thyroid Eye Disease.
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.
Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.
Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.
The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, and menstrual disorders.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease.
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.
Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.
Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.
The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, and menstrual disorders.
1. TEPEZZA (teprotumumab-trbw) [prescribing information] Horizon.
2. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. 3. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761. 4. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18)(suppl):1748-1761. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1614949/suppl_file/nejmoa1614949_appendix.pdf. 5. Wang Y, Patel A, Douglas RS. Thyroid eye disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305-1318. doi:10.2147/TCRM.S193018. 6. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726-738. 7. Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye (Lond). 2019;33(2):183-190. 8. Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease. Am J Ophthalmol. 2019;208:281-288.
